What peptide bioregulation actually is

science A peptide is a short chain of amino acids

Proteins and peptides are built from the same bricks — amino acids. What differs is length: a protein chain may hold hundreds or thousands of amino acids, while a peptide is normally a short chain. In the manufacturer’s scientific literature peptides are defined as short chains of amino acids that act in the body as bioregulators and take part in passing signals between cells and tissues.

Peptides are not foreign matter. They form continuously inside cells: a worn-out protein is broken down by enzymes and some of the fragments remain as short chains. The booklet Health Territory puts this almost as a rule — peptides are formed from protein, yet without peptides the synthesis of that same protein would not proceed.

The same literature stresses two points that are often confused. First, peptides are not hormones; their mechanism is described as a different one. Second, because they are not a foreign substance, the mammalian body takes them up without a rejection reaction.

How much is needed? The same source states that the body’s internal reserves cover about 90 percent of its peptide requirement, that the remainder is topped up from protein in food, and that after the age of 35 this capacity declines. That is a claim made in that literature rather than a promise from us — but the whole idea of the supplements grew out of it.

biotech Why chain length matters

A natural peptide chain is often longer than the interaction requires. The manufacturer’s booklet explains that what matters is one short sequence of two to five amino acids, and that this is regarded as the active part of the molecule. Most synthesised peptides are therefore copies of that active part of a natural peptide.

Why the sequence matters so much is set out in the Prime Peptide booklet: every peptide has a unique amino acid sequence which determines its three-dimensional structure and, with it, its functional specificity. Shape decides what the molecule can bind to at all. The press kit describes the same principle as an ability to “recognise” particular DNA sequences.

The consequences are very down-to-earth. A long mixture of chains isolated from tissue is hard to describe with a single formula; a short sequence can be written down exactly, reproduced synthetically and verified in production. This also stands behind the wording on the box — “peptide complex” and “short peptide” are not the same thing.

Length is also tied to quantity. The Prime Peptide booklet describes peptides as compounds of high biological activity that work in very small doses, because they do not do the work themselves but set off a cascade of biochemical reactions. That is why the pack shows micrograms rather than grams — not a marketing trick, but a property of this class of molecules as that literature describes it.

Chain length is indirectly tied to the product form as well: the catalogue states that in the sublingual lines the concentration of the active substance and the daily dose differ from the capsules. We cover that in the second article.

menu_book Where the idea came from

The peptide-bioregulation approach was formulated by Prof. Vladimir Khavinson (1946–2024), for many years head of the St Petersburg Institute of Bioregulation and Gerontology. These dates come from external references; they do not appear in the manufacturer's own literature.

Peptide bioregulation is tied to one institution — the St Petersburg Institute of Bioregulation and Gerontology. The company press kit describes it as a world-class research centre established by the academician Vladimir Khavinson, and states that the concept of peptide regulation of the body’s functions was formulated under his leadership, becoming the basis of a branch of modern gerontology.

The catalogue records the technical step: the technology for isolating low-molecular-weight peptide fractions was developed by staff of the Institute under V. Kh. Khavinson’s guidance. That technology became the basis for the class of preparations known collectively as cytomaxes.

The next stage was synthesis. Health Territory states that 21 peptides have been synthesised since 2000 and dates the cytogen generation to the 2000s. The sublingual single-peptide series, according to the same source, appeared later still.

The commercial side is younger than the scientific one. The company Peptides was founded in 2010, and in December 2019 an agreement was signed under which it became the Institute’s exclusive representative. The catalogue describes the relationship as years of collaboration on which all of the company’s development work rests.

Khavinson himself is presented in the press kit as the company’s Chief Scientific Advisor, Director of the Institute, President of the European Branch of the International Association of Gerontology and Geriatrics (IAGG) from 2011 to 2015, Chief Gerontologist of the St Petersburg Health Committee and a member of the Russian Academy of Sciences.

The same press kit lists the IAGG congresses attended: St Petersburg 2007, Bologna 2011, Seoul 2013, San Francisco 2017 and Gothenburg 2019. The catalogue mentions a joint project of the Institute and the company — a scientific information centre and library holding publications, reviews of clinical studies and video lectures by research staff. It is not an independent source, but it is where you can see what the field rests on.

auto_awesome How the literature describes the interaction with a cell

The explanatory model this school uses rests on a lock-and-key principle: a signalling molecule binds only where it fits geometrically and chemically. The other half of the model is tissue specificity — a peptide complex isolated from a particular organ is associated in the catalogue with the cells of that same organ.

The literature also describes a kind of safeguard that would stop a signal acting in the wrong place: some regions of DNA in a cell are covered by histone proteins, so a programme not meant for that cell is simply not read, however much of the signal arrives.

The Prime Peptide booklet tells the same story in other words: once in the body, a peptide binds to receptors on the cell membrane or enters the cell, where it interacts with specific genetic structures and signalling proteins.

The authors are plainly fond of a computing metaphor: the booklet compares peptide preparations to a package of software updates for the body as a biological system, and DNA to a store from which information is read only when the matching signal arrives. The metaphor is convenient and, for that very reason, misleading — a living cell is not a computer, and a comparison proves nothing.

It is worth being clear about the status of these statements. They are a research direction and an explanatory model set out in scientific and manufacturer literature. They are not a promise about what a capsule or a few drops will do for any particular person.

verified_user What peptide bioregulation does not mean

In the European Union these products are sold as food supplements. That has a very concrete consequence: an illness may not be given as the reason for taking a supplement, and a supplement may not be presented as something that removes an illness or wards one off. Regulation (EC) No 1924/2006 sets this out, and it is not a formality — wording of that kind gets products pulled from retail platforms.

The second point is where the literature comes from. A large share of the research this field rests on was carried out by a single scientific school and published mainly in Russian. That does not in itself make the work poor, but it does mean there are fewer independent replications in international peer-reviewed journals than one would like.

Third, the original manufacturer publications were written for the Russian market, where these products have a different legal status. The phrasing used there about illnesses and about “effectiveness” is not carried across into the description of a product sold in the EU. It is worth keeping that in mind if you read the original booklets or catalogues.

Fourth, you will notice what we do not repeat in these texts. The manufacturer publications assert many times over that these products carry no unwanted effects and that their effectiveness has been established. We do not carry wording of that kind across for a food supplement sold in the EU, and not because anything is being hidden: an absolute statement about safety is precisely the kind of statement a food supplement is not entitled to make.

So what can be said? What a peptide is, how the product is made, what is in it, what form it takes and how it is taken. That is what we do in this article and in the others.

inventory_2 How the theory turns into products

Three product families grew out of this research direction, and you will find all three in our catalogue.

The press kit sets the division out briefly: cytomaxes are based on naturally derived peptides, cytogens are synthesised from amino acids and are characterised by short molecules, and the products are available in capsule and sublingual form.

How the three families differ in composition, manufacture, concentration and dosing is covered in a separate article, “Cytomaxes, cytogens and sublingual drops — how they differ”.

Food supplement. A food supplement is not a substitute for medicine and is not intended to diagnose, treat or prevent any disease. Do not exceed the recommended daily dose. A food supplement should not be used as a substitute for a varied and balanced diet. Keep out of the reach of children. If pregnant, breastfeeding or taking medication, consult your doctor or pharmacist.

• Cytomaxes — natural peptide fractions isolated from animal organs and tissues; capsules.
• Cytogens — precisely defined short sequences synthesised from amino acids; capsules.
• Sublingual drops — the same cytomax or cytogen material in liquid form, in a 10 ml bottle with a dispenser.